Tarsus Pharmaceuticals (TARS) Amortization of Deferred Charges (2022 - 2026)
Tarsus Pharmaceuticals (TARS) posted quarterly Amortization of Deferred Charges of $159000.0 for Q1 2026, up 14.39% year-over-year from $139000.0 in Q1 2025, and up 1.92% quarter-over-quarter from $156000.0 in Q4 2025.
Powered by 
Analysis
Tarsus Pharmaceuticals (TARS) Amortization of Deferred Charges (2022 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' Amortization of Deferred Charges history runs 8 years deep, the most recent figure standing at $159000.0 for Q1 2026.
- In Q1 2026, Amortization of Deferred Charges rose 14.39% year-over-year to $159000.0; the TTM figure through Mar 2026 stood at $613000.0 (up 20.91% YoY), while the FY2025 annual figure was $593000.0, up 47.51% from the prior year.
- Amortization of Deferred Charges for Q1 2026 stood at $159000.0, up from $156000.0 in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $295000.0 in Q4 2023, with the low at -$96000.0 in Q4 2022.
- The 5-year median for Amortization of Deferred Charges is $114000.0 (2024), against an average of $95705.9.
- The sharpest annual moves came in 2022 and 2023: Amortization of Deferred Charges sank 132.65% in 2022, then soared 407.29% in 2023.
- Tarsus Pharmaceuticals' Amortization of Deferred Charges stood at -$96000.0 in 2022, then jumped by 407.29% to $295000.0 in 2023, then tumbled by 53.22% to $138000.0 in 2024, then grew by 13.04% to $156000.0 in 2025, then advanced by 1.92% to $159000.0 in 2026.
- Business Quant data shows TARS's Amortization of Deferred Charges at $159000.0 in Q1 2026, $156000.0 in Q4 2025, and $152000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Tarsus Pharmaceuticals | 3.96 Bn | 3.51 Bn | 161.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 165,000.00 |
| Mar 31, 2026 | 159,000.00 |
| Dec 31, 2025 | 156,000.00 |
| Sep 30, 2025 | 152,000.00 |
| Jun 30, 2025 | 146,000.00 |
| Mar 31, 2025 | 139,000.00 |
| Dec 31, 2024 | 138,000.00 |
| Sep 30, 2024 | 129,000.00 |
| Jun 30, 2024 | 101,000.00 |
| Mar 31, 2024 | 114,000.00 |
| Dec 31, 2023 | 111,000.00 |
| Sep 30, 2023 | 33,000.00 |
| Jun 30, 2023 | 28,000.00 |
| Mar 31, 2023 | 81,000.00 |
| Dec 31, 2022 | 78,000.00 |
| Sep 30, 2022 | 46,000.00 |
| Jun 30, 2022 | 35,000.00 |
| Mar 31, 2022 | 55,000.00 |